[EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER AU MOYEN D'AMIDES D'ACIDE O-AMINO-ALCANOIQUE A SUBSTITUTIONS AROMATIQUES ET DE DIAMIDES D'ACIDE ALCANOIQUE
申请人:ELAN PHARM INC
公开号:WO2003103652A1
公开(公告)日:2003-12-18
Disclosed.are methods for treating Alzheimer's disease, and other diseases,
and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of
A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables
R1, R2, R3, R4, R5, X1,
and X2 are defined herein.
Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds.
The present invention provides a fused ring compound of the following formula [I]
1
wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
申请人:Maillard Michel
公开号:US20060089355A1
公开(公告)日:2006-04-27
Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting de-position of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R
1
, R
2
, R
3
, R
4
, R
5
, X
1
, and X
2
are defined herein.
This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.